The first patient has been included in this clinical trial in Russia. The study is a Phase 2, Multi-Centre, Open-Label, Single-Arm Trial Investigating the Safety, Efficacy of IP aiming to help those suffering
Idiopathic pulmonary fibrosis is a chronic, progressive lung disease. When it occurs, scar tissue (fibrosis) is accumulated in the lungs, making it very difficult for the lungs to transport oxygen efficiently into the bloodstream.
“It is great news for the project and a milestone for GCT.
Due to the pandemic, it has become increasingly more complicated to conduct pulmonary studies as these sites are often prioritizing COVID-19 patients. Moreover, eligible patients pool narrowing as many protocols are being amended now to include only vaccinated patients. We are proud to say that our Russian team with collaboration with the site and Sponsor was able to deliver despite the changing requirements.” – Dr. Jeffrey Apter, GCT president.